SynthesisPloS one2018
Polygenic risk scores for major depressive disorder and neuroticism as predictors of antidepressant response: Meta-analysis of three treatment cohorts.
Synthesis in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pharmacogenomic scores in psychiatry: systematic review of current evidence.Translational psychiatry · 2024Pooled it
- Genetic contributions to alcohol use disorder treatment outcomes: a genome-wide pharmacogenomics study.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021Pooled it
- Polygenic heterogeneity in antidepressant treatment and placebo response.Translational psychiatry · 2022Trial
- Association of Molecular Senescence Markers in Late-Life Depression With Clinical Characteristics and Treatment Outcome.JAMA network open · 2022Trial
- Polygenic risk scores indicates genetic overlap between peripheral pain syndromes and chronic postsurgical pain.Neurogenetics · 2020Trial
- Genetic underpinnings of YMRS and MADRS scores variations in a bipolar sample.European archives of psychiatry and clinical neuroscience · 2026Article
- Interactive dynamic modulation of antidepressant treatment response by serum interleukin-1β and Neuroticism at 12 weeks.Scientific reports · 2026Article
- Genome-wide association and DNA methylation analyses of SSRI treatment response in major depressive disorder.BMC psychiatry · 2025Article
- Exploring depression treatment response by using polygenic risk scoring across diverse populations.American journal of human genetics · 2025Article
- Clinical, genetic, and sociodemographic predictors of symptom severity after internet-delivered cognitive behavioural therapy for depression and anxiety.BMC psychiatry · 2025Article
- Polygenic scores for precision psychiatry: a study on the effect heterogeneity of antidepressants.medRxiv : the preprint server for health sciences · 2025Article
- Association Between Polygenic Risk Scores and Treatment Response to Antidepressants, Benzodiazepines, and Antihistamines in Anxiety and Depression.Biological psychiatry global open science · 2025Article
- Polygenic score analysis identifies distinct genetic risk profiles in Alzheimer's disease comorbidities.Scientific reports · 2025Article
- Association of GLP1R locus with mental ill-health endophenotypes and cardiometabolic traits: A trans-ancestry study in UK Biobank.Diabetes, obesity & metabolism · 2025Article
- Childhood trajectories of emotional and behavioral difficulties are related to polygenic liability for mood and anxiety disorders.Journal of child psychology and psychiatry, and allied disciplines · 2025Article
- Polygenic scores contribution to Parkinson's disease comorbidities.Brain communications · 2025Article
- Novel psychedelic interventions for post-traumatic stress disorder and their promise for precision medicine.Therapeutic advances in psychopharmacology · 2025Review
- Polygenic scores and antidepressant treatment outcomes in major depression: a critical integrative review.Neuroscience applied · 2025Article
- Relationship between Polygenic Risk Score and the Hypnotics in Bipolar I Disorder.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2024Article
- Cross-EHR validation of antidepressant response algorithm and links with genetics of psychiatric traits.medRxiv : the preprint server for health sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
There are currently no reliable approaches for correctly identifying which patients with major depressive disorder (MDD) will respond well to antidepressant therapy. However, recent genetic advances suggest that Polygenic Risk Scores (PRS) could allow MDD patients to be stratified for antidepressant response. We used PRS for MDD and PRS for neuroticism as putative predictors of antidepressant response within three treatment cohorts: The Genome-based Therapeutic Drugs for Depression (GENDEP) cohort, and 2 sub-cohorts from the Pharmacogenomics Research Network Antidepressant Medication Pharmacogenomics Study PRGN-AMPS (total patient number = 760). Results across cohorts were combined via meta-analysis within a random effects model. Overall, PRS for MDD and neuroticism did not significantly predict antidepressant response but there was a consistent direction of effect, whereby greater genetic loading for both MDD (best MDD result, p < 5*10-5 MDD-PRS at 4 weeks, β = -0.019, S.E = 0.008, p = 0.01) and neuroticism (best neuroticism result, p < 0.1 neuroticism-PRS at 8 weeks, β = -0.017, S.E = 0.008, p = 0.03) were associated with less favourable response. We conclude that the PRS approach may offer some promise for treatment stratification in MDD and should now be assessed within larger clinical cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.